MedicineBiology
Alectinib (Alecensa) as First-line Option for ALK-positive Lung Cancer
M. Sheikh
2017.12.31Molecular and Cellular Pharmacology
tlooto Summary
Crizotinib (Xalkori) was the first ALK inhibitor approved by the FDA in 2013 for the treatment of ALK-positive NSCLC patients, however, resistance is noted within about one year of treatment with crizotin ib.
Abstract
Abstract is not available.
Citation format
SHEIKH, M. Alectinib (alecensa) as first-line option for ALK-positive lung cancer. Molecular and Cellular Pharmacology, 2017, 9: 15.